What Is Tesamorelin?
Tesamorelin is a growth hormone releasing hormone (ghrh) analogue supplied by Peptegrity for research and educational purposes. This page provides a factual educational overview of Tesamorelin, including its classification, biological target, research background, terminology and published study context. It is not a product page and does not provide dosing instructions, treatment recommendations or personal-use guidance.
Type of compound
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). It consists of a 44-amino acid peptide chain designed to simulate the biological activity of endogenous GHRH.
Biological target and mechanism
Tesamorelin functions by binding to and stimulating the growth hormone-releasing hormone receptor located on somatotroph cells in the anterior pituitary gland. This stimulation promotes the pulsatile secretion of endogenous growth hormone [1][3].
Research background
Research into tesamorelin has primarily focused on its influence on the growth hormone axis and metabolic parameters. Studies have investigated its impact on body composition, particularly adipose tissue distribution in specific clinical cohorts [2][4].
Current research and development status
Tesamorelin remains an investigational compound in many research contexts. While specific formulations have been studied in clinical trials, it is not approved by the FDA or TGA for general public use outside of strict regulatory and clinical trial frameworks [1][2].
Published research context
Published literature primarily investigates the metabolic implications of GHRH stimulation. Research has examined its effects on lipid profiles, abdominal fat, and insulin sensitivity in various patient populations [1][2][4].
Relevant terminology
An analogue is a chemical compound that is structurally similar to another but differs slightly in composition. Somatotrophs are pituitary cells responsible for the synthesis and secretion of growth hormone.
Storage and handling terminology
As a peptide, tesamorelin is generally sensitive to temperature and light degradation. Standard laboratory practice involves storing lyophilized powder at -20°C or colder for long-term stability and ensuring minimal exposure to air or moisture after reconstitution.
Testing and Certificate of Analysis (COA)
A Certificate of Analysis (COA) for research-grade peptides confirms identity, purity, and mass verification. Researchers typically look for high-performance liquid chromatography (HPLC) and mass spectrometry results to ensure the compound meets purity standards for experimental procedures.
Regulatory status
Tesamorelin is classified as a research chemical and is not approved as a medicine for human therapeutic use by major regulatory bodies. Any use of this substance must be strictly confined to authorized scientific or laboratory research environments.
This page is for research and educational purposes only. It is not intended to provide medical advice, dosing instructions, or treatment recommendations, and does not represent any product as approved to diagnose, treat, cure or prevent any disease. Compounds described here may be investigational or unapproved medicines; regulatory status is summarised for information only.
Frequently asked questions
What is Tesamorelin?
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) used as a tool in scientific research to study the stimulation of the growth hormone axis.
How does Tesamorelin function in a research setting?
In research, tesamorelin is used to investigate the activation of pituitary receptors, which induces the release of growth hormone in a manner similar to the endogenous hormone [3].
What is the regulatory status of Tesamorelin?
Tesamorelin is an investigational compound. It is not an approved medicine and its use is limited to laboratory or clinical research environments [2][4].
What areas of research have utilized Tesamorelin?
Research has primarily explored the metabolic effects of the compound, including its influence on fat distribution and endocrine responses in specific populations [1][2].
References
- 1.Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trialPubMed
- 2.Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension dataPubMed
- 3.TesamorelinPubMed
- 4.Growth hormone and tesamorelin in the management of HIV-associated lipodystrophyPubMed
